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Abstract
Protoapigenone, a natural flavonoid possessing an unusual p-quinol moiety on its B-ring, is a novel prospective anticancer
agent with low toxicity that is currently in development. The first economical, one-step synthesis of protoapigenone from
apigenin is described on up to gram scale. 13 new 19-O-alkylflavone analogs were also synthesized, either from apigenin or
b-naphthoflavone. The in vitro cytotoxic activity of each compound was tested on six human cancer cell lines (HepG2,
Hep3B, Ca9-22, A549, MCF-7 and MDA-MB-231). In the case of 19-O-alkyl-protoapigenone derivatives, structure-activity
relationships were found depending on the side-chain, and protoapigenone 19-O-butyl ether was found to exert
significantly stronger activity against three of the cell lines (Hep3B, MCF-7 and MDA-MB-231) than its non-substituted
analog, protoapigenone itself. In contrast to this, all b-naphthoflavone derivatives bearing the same pharmacophore on
their B-ring showed decreased cytotoxic activities when substituted with an O-alkyl side-chain at position 19, comparing to
that of the non-substituted compound.
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Introduction
Flavonoids are among the most widespread secondary plant
metabolites and play a significant role in the prevention of several
chronic diseases, including cancer [1–3]. Due to their numerous
anticancer functions, including antiproliferative, cell cycle arrest-
ing and pro-apoptotic effects, certain members of this chemical
group are believed to have potential not only in chemoprevention
but also as future chemotherapy agents for treating cancer [4,5].
Protoapigenone (1) was first isolated by our group from the
Formosan fern Thelypteris torresiana [6]. This compound has a close
structural and likely biosynthetic relationship with apigenin (2), a
common 49-hydroxy-flavone (Figure 1) that is abundantly present
in fruits and vegetables and is considered a particularly potent
cancer chemopreventive flavonoid, according to a growing body of
data [7,8].
In vitro, 1 exhibits significant antitumor activities toward HepG2,
Hep3B, MCF-7, A549 and MDA-MB-231 tumor cell lines (IC50
0.27–3.88 mg/mL). The compound was also found to induce
apoptosis in human prostate cancer cells [9] and to selectively
inhibit ovarian cancer cell growth both in vitro and in vivo in nude
mice while causing no major side effects in the latter case [10]. In a
recent study, 1 was shown to exert dose-dependent DNA damage,
apoptosis, and G2/M arrest at micromolar concentrations in a
lung cancer cell line (H1299) [11]. Based on its potent pro-
apoptotic activity and apparent low toxicity, 1 was chosen by the
National Science Council of Taiwan as the lead compound for the
development of a new class of anticancer drugs. Presently, in vivo
toxicology studies are being performed as part of the preclinical
phase, which have created a need for an economical way to
drastically increase the production of 1.
Figure 1. Structures of protoapigenone (1) and apigenin (2).
doi:10.1371/journal.pone.0023922.g001
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In 2007, a six-step total synthesis of 1 was reported by our group
[12]. After difficulties in carrying out the direct semisynthesis of 1
from 2, we used methoxymethyl-diprotected trihydroxyacetophe-
nones and 4-benzyloxybenzaldehyde as starting materials to
prevent the A-ring of 2 from oxidation, and we applied a
hypervalent iodine reaction to the 7-protected apigenin skeleton in
the second-to-last step to obtain the p-quinol moiety on the B-ring.
Finally, 1 was successfully obtained after the removal of the
protecting group. To carry out the key oxidation step that formed
the pharmacophore on the B-ring, we applied 2 equivalent (eq.) of
[bis(trifluoroacetoxy)iodo]benzene (commonly referred to as PIFA)
in the presence of 0.2 eq. of TEMPO, a commercially available
free radical catalyst. Although in some related oxidative
dearomatization reactions phenyliodine diacetate (PIDA) was
found to give higher yield of product as compared to when PIFA
was used [13], PIDA was less effective in our case. This was also in
accordance with the results of Wells et al. [14], who found the use
of PIFA and TEMPO advantegous over PIDA. Based on these,
PIFA was kept as the only oxidizing agent when the methodology
reported here was developed. The reaction was originally
performed by stirring at 25uC for 90 min in acetonitrile:water
(9:1, v/v) at a concentration of 18 mg/mL of 7-protected 2, and,
after deprotection, 1 was successfully obtained. Figure 2 shows an
outline of this procedure, including reaction times and isolated
yields of the reaction steps.
The procedure resulted in the synthesis of protoapigenone as
well as several of its derivatives which allowed SAR data to be
gathered. However, due to the long reaction times and the slow
chromatographic purifications, the procedure took approximately
one to two months to complete, and resulted in only a 3.3%
overall yield of 1. Because this means of production was unable to
satisfy the high material needs for the extensive preclinical
pharmacological investigation, the improvement of the synthetic
route has become an urgent need and a primary objective of our
research program.
Results and Discussion
Synthesis
Our attempt to improve the yield of the original method began
with the optimization of the oxidation of 7-MOM-apigenin but led
to the surprising observation that with appropriate reaction
conditions, 1 could be directly synthesized from 2 without the
need for protecting groups. Optimization of the direct semisynth-
esis provided the following insights:
– By decreasing the concentration of the starting material to
1 mg/mL, the yield could be improved significantly; further
decreases of concentration did not provide further increases in
the yield.
– TEMPO significantly decreases the yield, and the formation of
1 may be prevented completely by increasing the amount of
TEMPO used. Thus, it should be omitted from the reaction.
– The reaction is highly dependent on the solvent used. For
success, the majority of the solvent should be a non-
nucleophilic polar solvent, preferably acetonitrile. When using
acetone:water (9:1, v/v) and THF:water (9:1, v/v), the reaction
failed. EtOAc saturated with water gave traces of 1, while
1,1,1,3,3,3-hexafluoro-isopropanol:water (9:1, v/v) resulted in
about half the yield of that obtained using the ACN:water
mixture.
– Low energy microwave heating (70uC, 1 min, 500 W) can
increase the yield by more than two-fold, compared to when
the reaction is performed at room temperature.
– The TFA (trifluoroacetic acid) derived from the PIFA in the
reaction significantly decreases the pH. Compound 1 does not
suffer quick decomposition, but it is slightly sensitive to acidic
environments, so it is recommended that it be purified as soon
as possible. On the other hand, neutralizing the TFA is not
favorable, as the remaining ionizable phenolic hydroxyl groups
may lead to a less complete separation at the purification
process.
As mentioned above, we performed the reaction via a quick,
microwave-assisted oxidation of 2 (1 mg/mL in acetonitrile:water
9:1, v/v) with 2 eq. of PIFA, which resulted in a 31% isolated yield
for 100 mg of starting material. This was a great improvement
over the previous method [12]. The purification consisted of a
solid phase extraction followed by gel chromatography on
Sephadex LH-20, which also resulted in the isolation of two
side-products, 19 and 10. Based on its NMR spectra and chroma-
tographic properties in comparison with available testcompound
and literature data, 19 was identified as luteolin, a common flavone
and an expected side-product of the performed reaction [15]. By
means of ESI-MS and HRMS data, 10 was found to have a
molecular mass of 554 and a constitution of C30H18O11 corres-
ponding to an apigenin-protoapigenone dimer. The 1H NMR
spectrum suggested, that a ring corresponding to the B-ring of
apigenin is present (2H at both 7.38 and 6.77 ppm, J=8.8 Hz).
Interestingly, four separate hydrogens were shown as doublet-
Figure 2. The total-synthesis of protoapigenone as reported previously [12]. Reaction times and isolated yields are shown for each reaction
step. Purification of each intermediate product was performed by column chromatography on silica.
doi:10.1371/journal.pone.0023922.g002
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doublets with the larger coupling constant of 10.0 Hz. This
coupling would be characteristic to the two doublets, two
hydrogens each, of the B-ring of protoapigenone. Based on the
1H-1H COSY spectrum, these four hydrogens were also on the
same ring, suggesting a cyclohexadienone ring, as in protoapigen-
one, also to be present. Differences between the pairs of
corresponding protons on this ring are suggested to arise from
the effect of the close aromatic B-ring of the apigenin part, which
was also shown by NOESY correlations between hydrogens of
these two rings. The number of non-OH hydrogens and the
presence of only two meta-coupling doublets accompanied by two
singlets in the 1H spectrum suggested a C-C bond between parts of
the dimer. Further assignments were made based on the HMQC
and HMBC spectra, and an 8-30 junction was suggested.
Structure, numbering and key HMBC and NOESY correlations
of 10 are shown in Figure 3.
Hypervalent iodine reagents are widely used for the oxidative
dearomatization of 4-substituted phenols in the presence of an
appropriate nucleophile to obtain 4,4-disubstituted cyclohexadie-
nones [15–16], and reaction mechanisms involving carbocation
[13] and/or cation-radical [17] intermediates have been suggested
in the literature. Considering the structures of our isolated
products we suggest the mechanism shown in Figure 4.
The presence of 10 as a side-product also provides a possible
explanation for the failure of the previous conditions, which most
likely failed due to the much higher concentration of starting
material and thus the more favorable dimerization or even
oligomer formation via C-C coupling side-reactions. Considering
the large variety of other side-reactions also available in this
system, the 31% yield of 1 shows an unexpectedly good selectivity
of PIFA for the 49-OH group. This selectivity may arise from two
phenomena: (1) the greater acidity of the 7-OH group compared
to that of the 49-OH group (in a mixture of MeOH:water (1:2, v/v)
pKa = 6.9 and 8.6, respectively [18]) causes 2 to mostly exist in the
7-mono-anionic form at the neutral pH of the reaction’s start, and
(2) the intramolecular hydrogen-bond to the 5-OH group makes it
more stable than the 49-OH.
According to our main purpose of establishing a useful method
for larger scale production of 1, we scaled-up the procedure by
oxidizing 800.0 mg, 2.0 g and 5.0 g of 2, which provided
251.3 mg (29.6%), 546.2 mg (25.8%) and 1.18 g (22.3%) of 1,
respectively (see Materials and Methods section). Due to the large
volumes of solvent required (in order to prevent excessive side-
reactions, as mentioned above), further increases in the amount of
starting material used would have been difficult under laboratory
conditions. On the other hand, the solvent volume increase was
the most probable reason for the slight decrease of the yield on
larger scales, because it resulted in slower cooling after the reaction
was finished and a much longer evaporation process. This level of
productivity should, however, be suitable to obtain appropriate
amounts of 1 for the remaining preclinical studies.
The optimized reaction was also performed on 50.0 mg of b-
naphthoflavone (10), which served as the basis for the most active
synthetic derivative to date. This reaction yielded a remarkable
59% of the corresponding analog (11), compared to the 16% yield
reported previously [12].
For both starting materials 2 and 10, further derivatives were
also synthesized by replacing water with various alcohols to obtain
the corresponding 19-O-alkyl ethers, as shown in Figure 5.
In vitro activity
The cytotoxic activities of all protoapigenone analogs obtained
were tested on six human cancer cell lines, including HepG2 and
Hep3B (hepatic), Ca9-22 (oral), A549 (lung), as well as MCF-7
and MDA-MB-231 (breast) cancer cells, with doxorubicin as a
positive control. IC50 values and 95% confidence intervals of the
best fit values obtained by nonlinear regression are presented in
Table 1.
To elaborate on the findings of the previous investigation,
which showed that 19-O-methyl substitution decreases the activity
of 1 [12], the present results demonstrated that increasing the
length of a 19-O-alkyl side-chain on the protoapigenone skeletone
typically increases the activity comparing to that of the methyl-
substituted derivative (compound 3). As a result of this tendency,
several analogs were found to exert practically the same, or, as in
case of the butyl-substituted compound 7 against the Hep3B,
MCF-7 and MDA-MB-231 cell lines, even higher in vitro
cytotoxic activities comparing to that of the non-substituted
compound 1. On the other hand, a 20 to 30 unsaturated side-
chain (allyl, propargyl derivatives; 8, 9) decreased the activity on
the A549 cell line comparing to that of compound 5 bearing a
saturated propyl side-chain (p,0.05 and 0.001, respectively). In
addition to this, presence of a branching side-chain (isopropyl
derivative; 6) strongly decreased the activity on each cell line as
compared to that of 5 (p,0.01 in case of Ca9-22 and p,0.001 in
case of all other cell lines), resulting in low activities comparable
to those of the methyl-substituted compound 3. Figure 6 shows
the activities of all protoapigenone analogs on the Hep3B (A),
MCF-7 (B), and MDA-MB-231 (C) cell lines, where 7 was found
to exert significantly stronger activity than that of the lead
compound 1.
Interestingly, the activity of the b-naphthoflavone derivatives
(12–18) does not seem to follow the same trend, except for the
effect of the side-chain branching (isopropyl; 15, compared to the
Figure 3. Structure, numbering and key HMBC (A) and NOESY (B) correlations of 10.
doi:10.1371/journal.pone.0023922.g003
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propyl; 14) on most of the cell lines with the exception of A-549,
and all of these derivatives showed a marked decrease in the
activity as compared to that of 11.
These results may underline the importance of lipophilicity in
the activity of these compounds, which would also explain why
derivatives of the more lipophilic b-naphthoflavone as compared
to those of apigenin did not show a similar increase in activity
when length of the lipophilic side-chain was increased.
The fact, that a 19-O substitution of protoapigenone by a longer,
3 to 4 carbon aliphatic side-chain can restore, or, in case of some
cell lines, even increase the in vitro activity comparing to that of the
non-substituted compound, makes these derivatives, and particu-
larly compound 7, very interesting new candidates for in vivo
studies. Not only their increased lipophilicity will result in
significantly different pharmacokinetical properties and conse-
quential activity change, but we can also assume, that the 19-O-
alkylation may increase the stability of the pharmacophore B-ring
by protecting it from decomposition and/or metabolic conversion
via re-aromatization to the original flavone, apigenin in this case.
Conclusions
Our results can be summarized as the following:
1. The first economical method to obtain gram scale amounts of
protoapigenone was developed via its direct semisynthesis from
apigenin. This achievement is a great step forward for research
on this promising anticancer compound, considering the need
for large amounts of material to carry out toxicological studies.
2. Several new 19-O-alkyl-protoapigenone as well as the corre-
sponding b-naphthoflavone derivatives were synthesized. The
in vitro cytotoxicity assay of these compounds revealed, that in
case of the protoapigenone derivatives a longer aliphatic side-
Figure 4. Suggested reaction mechanism for the synthesis of 1 from 2 and product structures obtained.
doi:10.1371/journal.pone.0023922.g004
Figure 5. The reaction of 2 and 10 with PIFA in presence of water or various alcohols.
doi:10.1371/journal.pone.0023922.g005
Economic Synthesis of Protoapigenone & Derivatives
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23922
chain can be beneficial on the activity comparing to that of the
non-substituted protoapigenone, while this is not true in case of
the naphthoflavone derivatives.
3. Based on these findings, new candidates for further studies
were discovered, among which protoapigenone 19-O-butyl
ether (7) is the most promising one. The in vivo study of this
compound is planned in the near future, and the synthesis of
further derivatives is currently in progress.
Materials and Methods
General
Solvents, reagents and chromatographic stationary phases were
purchased from the following companies: solvents and octadecyl
silica from Merck Chemicals, PIFA and Sephadex LH-20 gel from
Sigma and b-naphthoflavone from Indofine Chemical Company
Ltd. (NJ, USA). Apigenin was synthesized from naringenine
(Indofine Ltd.) by Chuang DW in previous experiments (not
discussed here). All compounds tested possessed a purity of over
95%, except for 10 (89.1%), 3 (94.8%) and 6 (94.8%). Compound
purities were checked using HPLC-UV with one of the solvent
systems described below at 245 nm using a gradient system
consisting of two Jasco PU2080 LC pump and a Jasco UV2075
ultraviolet detector connected to a Hercule 2000 chromatographic
interface. Columns used: Agilent Zorbax XDB-C8, 5 mm,
15064.6 mm (RP-HPLC), and Agilent Zorbax-sil 5 mm, 2506
4.6 mm (NP-HPLC). Solvent systems: RP-HPLC1: 55% aqueous
MeOH increasing to 80% in 10 minutes; RP-HPLC2: 35% v/v
aqueous MeOH increasing to 80% in 10 minutes; NP-HPLC: 5%
Table 1. In vitro cytotoxic activities of the compounds obtained.
Compound IC50 (mM)
HepG2 Hep3B Ca9-22 A549 MCF-7 MDA-MB-231
1 3.07 (2.83–3.34) 1.21 (1.19–1.24) 0.78 0.49–1.24) 11.29 (10.07–12.65) 1.70 (1.58–1.82) 1.35 (1.17–1.55)
10 ,19.73 .36 16.89 (14.58–19.57) .36 .36 ,18.38
3 8.99 (6.12–13.21) 3.36 (3.19–3.54) 2.02 1.64–2.49) 21.78 (20.41–23.24) 6.76 (6.07–7.53) 2.82 (2.61–3.04)
4 8.27 (8.03–8.51) 1.73 (1.68–1.78) 1.00 (0.81–1.24) 13.45 (12.01–15.07) 3.15 (2.23–4.45) 1.57 (1.45–1.71)
5 ,6.90 1.66 (1.65–1.68) 0.81 (0.80–0.82) 12.39 (11.04–13.91) 2.36 (2.06–2.69) 1.26 (1.04–1.53)
6 ,19.70 3.59 (3.08–4.19) 1.80 (0.89–3.65) 20.06 (16.22–24.80) 11.43 (10.81–12.09) 2.30 (2.06–2.56)
7 8.78 (8.10–9.51) 0.82(*) (0.80–0.83) ,0.70 10.76 (9.25–12.51) 1.38(*) (1.32–1.44) 0.62(***) (0.47–0.81)
8 7.92 (7.74–8.10) 1.61 (1.54–1.67) 0.93 (0.88–0.98) 17.02 (16.14–17.94) 2.47 (2.26–2.70) 1.53 (1.41–1.66)
9 ,7.81 1.20 (1.19–1.21) 0.89 (0.83–0.96) 20.35 (17.33–23.91) 2.32 (2.14–2.54) 1.75 (1.58–1.93)
11 1.06 (1.04–1.08) 0.25 (0.20–0.30) 0.23 (0.16–0.33) 2.19 (2.03–2.37) ,0.61 0.43 (0.41–0.45)
12 19.48 (17.02–22.30) 0.98 (0.90–1.06) 0.82 (0.73–0.92) 23.17 (20.91–25.68) 2.03 (1.78–2.32) 1.32 (1.18–1.46)
13 9.96 (8.64–11.49) 0.85 (0.83–0.86) 1.03 (0.94–1.21) 17.88 (15.26–20.95) 3.45 (3.10–3.83) 1.68 (1.55–1.81)
14 10.53 (8.68–12.77) 0.88 (0.85–0.91) 0.79 (0.77–0.81) 21.72 (16.81–28.07) 2.92 (2.49–3.44) 1.46 (1.34–1.59)
15 19.21 (17.00–21.71) 2.48 (1.98–3.11) 2.18 (1.73–2.73) 20.66 (18.00–23.72) 2.33 (2.10–2.59) 2.97 (2.66–3.31)
16 7.96 (7.85–8.06) 0.94 0.85–1.03) 1.01 (0.89–1.15) 15.66 (14.90–16.45) 3.05 (2.50–3.72) 1.70 (1.56–1.84)
17 9.43 (9.32–9.55) 0.85 (0.81–0.90) 0.83 (0.81–0.86) 15.38 (14.00–16.90) 2.28 (2.14–2.43) 1.46 (1.37–1.56)
18 8.14 (7.82–8.47) 0.88 (0.73–1.05) 0.86 (0.85–0.87) 19.30 (17.10–21.79) 2.24 (2.10–2.40) 1.89 (1.68–2.12)
D 0.83 0.49–1.39 1.14 (0.78–1.69) 0.60 (0.47–0.76) ,1.86 1.24 (0.76–2.00) ,1.73
Individual IC50 values were compared to those of 1 (in case of 3–9) or 11 (in case of 12–18) by one way ANOVA and Dunnet’s Multiple Comparison Test and by
unpaired T-tests in case of compounds 7 and 1 (Hep3B and MCF7 only). Significantly stronger activities than that of the reference compound are only marked. n = 3;
*: p,0.05 by unpaired T-test, while variances were not significantly different;
***: p,0.001 by ANOVA;
,: ambiguous fitting, very wide confidence intervals; D: doxorubicin.
doi:10.1371/journal.pone.0023922.t001
Figure 6. In vitro cytotoxic activities of the protoapigenone
analogs against the Hep3B, MCF-7 and MDA-MB-231 cell lines.
Numbers on the abscissa represent the corresponding compounds,
while charts A, B and C represent activities against Hep3B, MCF-7 and
MDA-MB-231 cell lines, respectively. Error bars represent the 95%
confidence intervals of the IC50 values; doxorubicin: ambiguous fitting,
no confidence interval available. Significantly stronger activities
comparing to that of 1 are marked; *: p,0.05 by unpaired T-test; ***:
p,0.001 by ANOVA.
doi:10.1371/journal.pone.0023922.g006
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v/v isopropanol in dichloromethane increasing to 17% in 12 min-
utes and flow rate was 1 mL/min in each case. Chromatograms are
shown in Figures S4–S20. 1H NMR spectra were taken using a
Varian Gemini-2000 200 MHz FT-NMR, and 13C and 2D NMR
spectra were taken using a Varian Mercury-plus 400 MHz FT-
NMR spectrometer. Shifts are given in ppm downfield of TMS and
were referenced to internal residual protosolvent. 1H NMR spectra
of all new compounds are shown in Figures S21–S60. These spectra
were taken prior to crystallization, while activity assays and HPLC
were done with the pure crystals obtained for all compounds, except
for 10 which could not be crystallized. Hence, Figures S22–S60. do
not represent final purity and are only shown to assist interpretation
of NMR data. Mass spectra were measured on a PECIEX API 3000
instrument with a turbo ion spray source, Agilent-1100, LC/MSD-
Trap, or Shimadzu LCMS-IT-TOF with an ESI interface.
Crystallographic data for structural analysis have been deposited
with the Cambridge Crystallographic Data Centre (deposition
numbers CCDC 762721–762723). These data sets can be obtained
free of charge via www.ccdc.cam.ac.uk/conts/retrieving html, email:
(or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK;
fax: +44 1223 336 033; e-mail: deposit@ccdc.camac.uk). The
melting points were measured on VEBWagetechnik Rapido PHNK
melt microscope (upper limit: 360uC). The structures of 1, 19, 11 and
12 were determined based on literature data [6,12,19], their melting
points were found 183–184uC (lit. for 1 of natural origin: 180–181uC
[6]), 328–330 (lit. for 19 of natural origin: 328–330uC [20]), 197–
198uC and 171–183uC, respectively. HPLC and purity data for the
known compounds 1, 11 and 12 are as follows. 1. RP-HPLC1:
7.057 min (Figure S4), purity: 95.9%. 11. NP-HPLC: 9.733 min
(Figure S13), purity: 98.8%. 12. NP-HPLC: 10.580 min (Figure
S14), purity: 99.5%. Yields given represent isolated yields.
Assay for Cytotoxicity
Human breast (MCF-7 and MDA-MB-231), liver (HepG2 and
Hep3B), and lung (A549) cancer cell lines were obtained from the
American Type Culture Collection. The human oral squamous
cell carcinoma Ca9-22 was a kind gift from Dr. Jeff Yi-Fu Chen,
Kaohsiung Medical University, Kaohsiung, Taiwan. All cell lines
were propagated in RPMI-1640 medium supplemented with 10%
(v/v) FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin at
37uC in a humidified atmosphere of 5% CO2 and 95% air. Cell
viability was measured by the MTT colorimetric method [21].
Cells were seeded at densities of 5,000 to 10,000 cells/well in 96-
well tissue culture plates. On day two, cells were treated with the
test compounds for another 72 h. After drug treatment, attached
cells were incubated with MTT (0.5 mg/mL, 1 h) and subse-
quently solubilized in DMSO. The absorbtion at 550 nm was then
measured using a microplate reader. The IC50 was recorded as the
concentration of the agent that reduced cell viability by 50%
under the experimental conditions, and it was determined by
applying variable slope nonlinear regression with automatic outlier
elimination at Q=1.0% by using GraphPad Prism 5.0 (GraphPad
Software Inc.). Statistical evaluation of the individual IC50 values
was done by one way ANOVA with Dunnet’s Multiple
Comparison Test by choosing compounds 1 and 11 as references
to their corresponding 19-O-alkylated analogs. To reveal structure-
activity relationships, the activites of each compound were
compared by Bonferroni tests, and, in case of comparing the
activities of 1 and 7, unpaired T-tests were also performed.
General procedure for 1
Compound 2 (100.0 mg) was dissolved in ACN:water (9:1, v/v;
100 mL). A quantity of PIFA (318.0 mg, 2 eq.) was added to the
container, and microwave heating was applied (70uC, max. power
500 W, 1 min) with continuous stirring. The resulting mixture was
evaporated, adsorbed onto 2.0 g of octadecyl silica, layered on the
top of 2.0 g of octadecyl silica, washed with 10 mL of 20%
aqueous MeOH and eluted with 20 mL of 60% aq. MeOH. The
latter fraction was evaporated, redissolved in MeOH, and purified
on a Sephadex LH-20 column (385620 mm; eluent: MeOH).
Fractions of 10 mL were collected, and fractions 11 through 14
gave protoapigenone (33.0 mg, 31.2%). The side-products 19 and
10 were isolated from fractions 15 through 18 and 19 through 21,
respectively, with repeated purification on the same Sephadex LH-
20 column.
Scale-up procedure for 1
Different quantities of 2 (800.0 mg, 2.0 g, and 5.0 g) were
dissolved in ACN:water (9:1, v/v; 800 mL, 2 L and 5 L) in
staunch containers that were then pre-heated to 70uC. After
releasing the pressure, PIFA (2 eq.; 2.55 g, 6.37 g and 15.93 g)
was added to each solution in a careful manner to prevent sudden
explosive boiling, and after re-sealing the containers, microwave
heating was applied (70uC, max. 500 W, 3 min) with continuous
stirring. The samples obtained were cooled under a stream of
water and subsequently with an ice bath. Each sample was
immediately evaporated in a 10 L roundbottom flask using a
Bu¨chi Rotavapor R-220 at 50uC. After redissolving them, the
samples were adsorbed onto octadecyl silica (16.0 g, 40.0 g or
100.0 g) that was layered on top of the same amount of octadecyl
silica. SPE was performed by eluting with 15% aqueous MeOH
(80 mL, 200 mL or 500 mL) followed by 50% aqueous MeOH
(200 mL, 500 mL and 1200 mL. The fractions containing 50%
MeOH were purified on silica gel with CH2Cl2-MeOH (20:1, v/v)
to give 251.3 mg (29.6%), 546.2 mg (25.8%) and 1.18 g (22.3%) of
protoapigenone, respectively.
General procedure for 3 through 9 and 11 through 18
A total of 50.0 mg of 2 or 10 was dissolved in 50 mL of a 9:1 v/
v mixture of acetonitrile and the corresponding alcohol (MeOH,
EtOH, PrOH, iPrOH, BuOH, allyl alcohol or propargyl alcohol)
or water in the case of 11 and reacted with PIFA (159 mg or
150 mg, 2 eq.) under the same conditions used to obtain 1. To
purify the products, flash chromatography (Biotage Flash+) on
silica columns (Biotage Si 24+M 2758-1; 116150 mm) was
performed using a dry-loading technique and n-hexane:EtOAc:a-
cetone solvent systems (all ratios are given in v/v/v; 7:3:1 for 3–5,
9:3:1 for 6, 8 and 9, and 11:3:1 for 7 each containing 0.01% TFA,
as well as 16:3:1 for 11 and 12, 27:3:1 for 13, 36:3:1 for 14, 15, 17
and 18, and 44:3:1 for 16 (no added acid was used)) at flow rates of
24 mL/min. Finally, 3 through 9 and 12 were crystallized from
hexane:acetone (1:1, v/v), while 13 through 18 were crystallized
from hexane:CH2Cl2 (1:1, v/v).
Experimental
Protoapigenone-(8-30)-apigenin (10). Yield: 4% (8.2 mg) as
a side-product of the reaction of 2 into 1; RP-HPLC2: 6.843 min
(Figure S5), purity: 89.1%; yellow solid, mp: .360uC, 1H NMR
(acetone-d6) d 12.87 (1H, s, OH-50), 12.65 (1H, s, OH-5), 7.38
(2H, d, J=8.8 Hz, H-209 and H-309), 6.81 (1H, dd, J=10.0,
3.2 Hz, H-29 or H-69), 6.78 (2H, d, J=8.8 Hz, H-309 and H-509),
6.76 (1H, dd, J=9.6, 3.2 Hz, H-69 or H-29), 6.57 (1H, s, H-3),
6.50 (1H, d, J=2.0 Hz, H-80), 6.30 (1H, s, H-6), 6.29 (1H, d,
J=2.0 Hz, H-60), 6.08 (1H, dd, J=10.0, 2.0 Hz, H-39 or H-59),
5.85 (1H, dd, J=10.0, 1.6 Hz, H-59 or H-39) (Figures S21 and
S22); 13C NMR (acetone-d6) d 185.2 (C-49), 184.1 (C-4), 182.5 (C-
40), 168.8 (C-2), 165.8 (C-70), 165.4 (C-20), 164.0 (C-8a), 163.9 (C-
7, C-50), 163.5 (C-5), 161.4 (C-409), 159.5 (C-8a0), 148.1 (C-29 or
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C-69), 148.0 (C-69 or C-29), 131.6 (C-209, C-609), 130.6 (C-39 or C-
59), 130.5 (C-59 or C-39), 125.3 (C-109), 116.7 (C-309, C-509), 111.3
(C-30), 108.0 (C-3), 106.1 (C-4a), 105.3 (C-4a0), 101.3 (C-8), 100.5
(C-6), 100.3 (C-60), 95.4 (C-80), 71.3 (C-19); ESI-MS (m/z, %): 555
(M++H, 100), 577 (M++Na, 92); HRMS: C30H18O11Na,
calculated 577.0747; found 577.0750.
Protoapigenone 19-O-methylether (3). Yield: 42% (23.3
mg); RP-HPLC1: 3.860 min (Figure S6), purity: 94.8%; white
crystals, mp: 153–155uC, 1H NMR (acetone-d6) d 12.59 (1H, br,
OH-5), 6.99 (2H, d, J=10.2 Hz, H-29 and H-69), 6.55 (2H, d,
J=10.2 Hz, H-39 and H-59), 6.50 (1H, s, H-3), 6.29 (1H, d,
J=2.0 Hz, H-8), 6.24 (1H, d, J=2.0 Hz, H-6), 3.42 (3H, s,
OCH3-19) (Figures S23 and S24);
13C NMR (acetone-d6) d 183.4
(C-49), 181.6 (C-4), 164.7 (C-2), 164.0 (C-7), 162.0 (C-5), 157.5 (C-
8a), 144.8 (C-29 and C-69), 132.4 (C-39 and C-59), 106.9 (C-3),
104.3 (C-4a), 98.8 (C-6), 93.5 (C-8), 74.2 (C-19), 51.6 (C-10); ESI-
MS (m/z, %): 323 (M++Na, 100), 301(M++H, 82); HRMS:
C16H12O6Na, calculated 323.0532; found 323.0530.
Protoapigenone 19-O-ethylether (4). Yield: 33% (19.2 mg);
RP-HPLC1: 5.157 min (Figure S7), purity: 96.7%; white crystals,
mp: 170–172uC, 1H NMR (acetone-d6) d 12.59 (1H, br, OH-5),
7.01 (2H, d, J=10.2 Hz, H-29 and H-69), 6.56 (1H, s, H-3), 6.51
(2H, d, J=10.0 Hz, H-39 and H-59), 6.28 (1H, br, H-8), 6.24 (1H,
br, H-6), 3.63 (2H, q, J=3.5 Hz, H-10), 1.27 (3H, s, H-20) (Figures
S25, S26 and S27); 13C NMR (acetone-d6) d 183.6 (C-49), 181.7
(C-4), 164.9 (C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.3 (C-
29 and C-69), 131.9 (C-39 and C-59), 106.9 (C-3), 104.3 (C-4a),
98.7 (C-6), 93.4 (C-8), 74.0 (C-19), 60.0 (C-10), 14.6 (C-20); ESI-
MS (m/z, %): 337 (M++Na, 100), 315 (M++H, 96); HRMS
C17H14O6Na, calculated 337.0688; found 337.0686.
Protoapigenone 19-O-propylether (5). Yield: 36%
(21.9 mg); RP-HPLC1: 8.240 min (Figure S8), purity: 97.8%;
white crystals, mp: 181–182uC, 1H NMR (acetone-d6) d 12.59
(1H, br, OH-5), 7.01 (2H, d, J=10.2 Hz, H-29 andH-69), 6.56 (1H,
s, H-3), 6.52 (2H, d, J=10.2 Hz, H-39 and H-59), 6.28 (1H, d,
J=2 Hz, H-8), 6.24 (1H, d, J=2 Hz, H-6), 3.54 (2H, t, J=6.3 Hz,
H-10), 1.68 (2H, m, H-20), 0.98 (3H, t, J=7.3 Hz, H-30) (Figures
S28, S29 and S30); 13C NMR (acetone-d6) d 183.6 (C-49), 181.7 (C-
4), 164.8 (C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.4 (C-29
and C-69), 131.9 (C-39 and C-59), 106.9 (C-3), 104.3 (C-4a), 98.7 (C-
6), 93.5 (C-8), 74.0 (C-19), 65.9 (C-10), 22.7 (C-20), 9.6 (C-30); ESI-
MS (m/z, %): 329 (M++H, 100), 351 (M++Na, 80); HRMS
C18H16O6Na, calculated 351.0845; found 351.0846.
Protoapigenone 19-O-isopropylether (6). Yield: 26%
(15.8 mg); RP-HPLC1: 7.637 min (Figure S9), purity: 94.9%;
light-brownish crystals, mp: 138–140uC, 1H NMR (acetone-d6) d
12.59 (1H, br, OH-5), 7.07 (2H, d, J=9.8 Hz, H-29 and H-69),
6.56 (1H, s, H-3), 6.50 (2H, d, J=9.8 Hz, H-39 and H-59), 6.28
(1H, br, H-8), 6.24 (1H, br, H-6), 3.94 (1H, m, J=6.1 Hz, H-10),
1.24 (6H, d, J=6.2 Hz, H-20 and H-30) (Figures S31, S32, S33
and S34); 13C NMR (acetone-d6) d 162.0 (C-5), 145.7 (C-29 and
C-69), 131.3 (C-39 and C-59), 107.0 (C-3), 104.2 (C-4a), 98.7 (C-6),
93.4 (C-8), 68.0 (C-10), 23.5 (C-20 and C-30); ESI-MS (m/z, %):
329 (M++H, 100), 351 (M++Na, 84), 270 (M++H – OC3H6, 16);
HRMS C18H16O6Na, calculated 351.0845; found 351.0844.
Protoapigenone 19-O-butylether (7). Yield: 44% (27.9 mg);
RP-HPLC1: 9.437 min (Figure S10), purity: 96.1%; white crystals,
mp: 167–168uC, 1H NMR (acetone-d6) d 12.60 (1H, br, OH-5),
7.01 (2H, d, J=10.8 Hz, H-29 and H-69), 6.55 (1H, s, H-3), 6.52
(2H, d, J=10.8 Hz, H-39 and H-59), 6.28 (1H, br, H-8), 6.25 (1H,
br, H-6), 3.58 (2H, t, J=6.0 Hz, H-10), 1.63 (2H, m, br, H-20), 1.44
(2H, m, br, H-30), 0.93 (3H, t, J=7.2 Hz, H-40) (Figures S35, S36
and S37); 13C NMR (acetone-d6) d 183.6 (C-49), 181.7 (C-4), 164.9
(C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.4 (C-29 and C-69),
132.0 (C-39 and C-59), 106.9 (C-3), 104.3 (C-4a), 98.7 (C-6), 93.4 (C-
8), 74.0 (C-19), 64.1 (C-10), 31.5 (C-20), 18.6 (C-30), 12.8 (C-40);
HRMS C19H18O6Na, calculated 365.1001; found 365.1000.
Protoapigenone 19-O-allylether (8). Yield: 29% (17.5 mg);
RP-HPLC1: 8.283 min (Figure S11), purity: 97.2%; transparent
crystals, 1H NMR (acetone-d6) d 12.59 (1H, br, OH-5), 7.04 (2H,
d, J=10.2 Hz, H-29 and H-69), 6.57 (1H, s, H-3), 6.53 (2H, d,
J=10.4 Hz, H-39 and H-59), 6.29 (1H, d, J=2.2 Hz, H-8), 6.24
(1H, J=2.2 Hz, H-6), 6.00 (1H, m, J=5.4 Hz, H-20), 5.37 (1H, d,
J=17.2 Hz, H-30, cis), 5.20 (1H, d, J=10.4 Hz, H-30, trans), 4.14
(2H, J=5.2 Hz, H-10) (Figures S38 and S39); 13C NMR (acetone-
d6) d 164.9 (C-2), 163.9 (C-7), 162.0 (C-5), 157.5 (C-8a), 145.4 (C-
29 and C-69), 132.0 (C-39 and C-59), 106.9 (C-3), 98.7 (C-6), 93.4
(C-8), 72.9 (C-19), 65.9 (C-10); ESI-MS (m/z, %): 349 (M++Na,
100), 327 (M++H, 85); HRMS C18H14O6Na, calculated 349.0688;
found 349.0690; X-ray data are shown in Figure S1.
Protoapigenone 19-O-propargylether (9). Yield: 36%
(21.6 mg); RP-HPLC1: 4.180 min (Figure S12), purity: 97.4%;
yellow crystalline powder, mp: 205–207uC, 1H NMR (acetone-d6)
d 12.55 (1H, s, OH-5), 7.08 (2H, d, J=10.0 Hz, H-29 and H-69),
6.55 (2H, d, J=10.2 Hz, H-39 and H-59), 6.53 (1H, s, H-3), 6.30
(1H, d, J=2.2 Hz, H-8), 6.24 (1H, d, J=2.0 Hz, H-6), 4.34 (2H,
d, J=2.4 Hz, H-10), 3.11 (1H, t, J=2.4 Hz, H-30) (Figures S40
and S41, 400 MHz 1H spectrum is also provided in Figure S42);
13C NMR (acetone-d6) d 185.4 (C-49), 183.5 (C-4), 166.1 (C-2),
166.0 (C-7), 163.9 (C-5), 159.4 (C-8a), 145.9 (C-29 and C-69),
134.3 (C-39 and C-59), 109.0 (C-3), 106.2 (C-4a), 100.8 (C-6), 95.4
(C-8), 81.3 (C-19), 78.0 (C-30), 76.4 (C-20), 54.8 (C-10); HRMS
C18H12O6Na, calculated 347.0532; found 347.0535.
3-(1-Ethoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (13). Yield: 65% (37.5 mg); NP-HPLC: 7.507
min (Figure S15), purity: 99.8%; white crystals, mp: 158–160uC,
1H NMR (CDCl3) d 9.97 (1H, d, J=8.4 Hz, H-5), 8.04 (1H, d,
J=8.8 Hz, H-9), 7.87 (1H, dd, J=7.6, 1.0 Hz, H-8), 7.74 (1H, td,
J=8.4, 1.4 Hz, H-7), 7.60 (1H, td, J=8.0, 1.0 Hz, H-6), 7.36
(1H, d, J=9.2 Hz, H-10), 6.95 (1H, s, H-3), 6.89 (2H, d,
J=10.2 Hz, H-29 and H-69), 6.55 (2H, d, J=10.4 Hz, H-39 and
H-59), 3.61 (2H, q, J=7.0 Hz, H-10), 1.307 (3H, t, J=7.0 Hz, H-
20) (Figures S43, S44 and S45); 13C NMR (CDCl3) d 184.2 (C-49),
179.5 (C-4), 160.9 (C-2), 156.9 (C-10a), 145.8 (C-29 and C-69),
132.2 (C-39 and C-59), 135.3, 130.2, 129.9, 129.0, 127.8, 126.6,
126.4 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9), 116.9 (C-10), 116.9
(C-4a), 112.1 (C-3), 73.9 (C-19), 60.5 (C-10), 15,3 (C-20); ESI-MS
(m/z, %): 355 (M++Na, 100), 333 (M++H, 79); HRMS
C21H16O4Na, calculated 355.0946; found 355.0945.
3-(1-Propoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (14). Yield: 64% (38.4 mg); NP-HPLC: 5.977
min (Figure S16), purity: 98.9%; transparent crystals, 1H NMR
(CDCl3) d 9.96 (1H, d, J=8.8 Hz, H-5), 8.01 (1H, d, J=9.0 Hz, H-
9), 7.85 (1H, d, br, J=8.0 Hz, H-8), 7.73 (1H, td, J=7.0, 1.6 Hz, H-
7), 7.58 (1H, td, J=8.0, 1.2 Hz, H-6), 7.33 (1H, d, J=9.2 Hz, H-
10), 6.92 (1H, s, H-3), 6.87 (2H, d, J=9.8 Hz, H-29 and H-69), 6.55
(2H, d, J=10.2 Hz, H-39 and H-59), 3.50 (2H, t, J=6.2 Hz, H-10),
1.68 (2H, sextet, J=7.0 Hz, H-20), 0.99 (3H, t, J=7.3 Hz, H-30)
(Figures S46, S47 and S48); 13C NMR (CDCl3) d 145.8 (C-29 and C-
69), 132.2 (C-39 and C-59), 135.3, 129.0, 127.8, 126.6, 126.4 (C-4b,
C-7, C-8, C-8a, C-9), 116.9 (C-10), 116.9 (C-4a), 112.1 (C-3), 73.9
(C-19), 66.5 (C-10), 23.0 (C-20), 10.2 (C-30); ESI-MS (m/z, %): 369
(M++Na, 100), 347 (M++H, 60); HRMS C22H18O4Na, calculated
369.1103; found 369.1105; X-ray data are shown in Figure S2.
3-(1-Isopropoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (15). Yield: 52% (31.2 mg); NP-HPLC:
6.307 min (Figure S17), purity: 99.0%; transparent crystals, 1H
NMR (CDCl3) d 9.97 (1H, d, J=8.8 Hz, H-5), 8.03 (1H, d,
Economic Synthesis of Protoapigenone & Derivatives
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23922
J=9.0 Hz, H-9), 7.94 (1H, d, br, J=8.2 Hz, H-8), 7.74 (1H, td,
J=7.8, 1.0 Hz, H-7), 7.60 (1H, td, J=7.6, 1.0 Hz, H-6), 7.35
(1H, d, J=9.2 Hz, H-10), 6.94 (1H, s, H-3), 6.91 (2H, d,
J=10.6 Hz, H-29 and H-69), 6.53 (2H, d, J=9.8 Hz, H-39 and
H-59), 3.89 (1H, septet, J=6.2 Hz, H-10), 1.24 (6H, d, J=6.2 Hz,
H-20 and H-30) (Figures S49, S50 and S51); 13C NMR (CDCl3) d
184.5 (C-49), 179.6 (C-4), 161.2 (C-2), 156.9 (C-10a), 146.2 (C-29
and C-69), 131.5 (C-39,C-59), 135.3, 130.2, 129.9, 129.0, 127.7,
126.6, 126.4 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9), 116.9 (C-10),
116.9 (C-4a), 112.2 (C-3), 74.1 (C-19), 68.5 (C-10), 24.3 (C-20 and
C-30); ESI-MS (m/z, %): 369 (M++Na, 100), 347 (M++H, 54);
HRMS C22H18O4Na, calculated 369.1103; found 369.1104.
3-(1-Butoxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (16). Yield: 54% (33.8 mg); NP-HPLC:
5.230 min (Figure S18), purity: 95.8%; transparent crystals, mp:
72–73uC, 1H NMR (CDCl3) d 9.97 (1H, d, J=8.8 Hz, H-5), 8.03
(1H, d, J=9.2 Hz, H-9), 7.86 (1H, d, br, J=8.0 Hz, H-8), 7.74 (1H,
td, J=8.4, 1.6 Hz, H-7), 7.59 (1H, td, J=7.6, 1.6 Hz, H-6), 7.34
(1H, d, J=9.0 Hz, H-10), 6.92 (1H, s, H-3), 6.87 (2H, d,
J=10.2 Hz, H-29 and H-69), 6.55 (2H, d, J=10.4 Hz, H-39 and
H-59), 3.54 (2H, t, J=6.2 Hz, H-10), 1.65 (2H, m, J=7.0 Hz, H-20),
1.45 (2H, m, J=7.3 Hz, H-30), 0.95 (3H, t, J=7.4 Hz, H-40)
(Figures S52, S53 and S54); 13C NMR (CDCl3) d 184.3 (C-49), 179.5
(C-4), 160.1 (C-2), 156.9 (C-10a), 145.9 (C-29 and C-69), 132.2 (C-39
and C-59), 135.3, 130.2, 129.9, 129.0, 127.8, 126.6, 126.4 (C-4b, C-
5, C-6, C-7, C-8, C-8a, C-9), 116.9 (C-10), 116.9 (C-4a), 112.1 (C-3),
73.8 (C-19), 64.6 (C-10), 31.7 (C-20), 18.8 (C-30), 13.4 (C-40); ESI-MS
(m/z, %): 383 (M++Na, 100), 361 (M++H, 65); HRMSC23H20O4Na,
calculated 383.1259; found 383.1258.
3-(1-Allyloxy-4-oxocyclohexa-2,5-dienyl)-1H-benzo[f]
chromen-1-one (17). Yield: 51% (30.5 mg); NP-HPLC:
6.650 min (Figure S19), purity: 98.0%; transparent crystals, mp:
148–150uC, 1H NMR (CDCl3) d 9.96 (1H, d, J=8.2 Hz, H-5),
8.03 (1H, d, J=8.8 Hz, H-9), 7.86 (1H, d, br, J=8.2 Hz, H-8),
7.74 (1H, td, J=8.4, 1.4 Hz, H-7), 7.60 (1H, td, J=7.6, 1.0 Hz,
H-6), 7.35 (1H, d, J=9.2 Hz, H-10), 6.94 (1H, s, H-3), 6.91 (2H,
d, J=11.0 Hz, H-29 and H-69), 6.57 (2H, d, J=10.2 Hz, H-39
and H-59), 5.95 (1H, m, J=5.0 Hz, H-20), 5.38 (1H, dd, J=18.8,
1.6 Hz, H-30, cis), 5.25 (1H, dd, J=10.4, 1.6 Hz, H-30, trans),
4.09 (2H, J=5.6 Hz, H-10) (Figures S55, S56 and S57); 13C NMR
(CDCl3) d 184.1 (C-49), 179.4 (C-4), 160.6 (C-2), 156.9 (C-10a),
145.3 (C-29 and C-69), 132.4 (C-39 and C-59), 135.3, 130.2, 129.9,
129.0, 127.8, 126.6, 126.4 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9),
116.9 (C-10), 116.9 (C-4a), 112.2 (C-3), 74.1 (C-19), 65.7(C-10),
133.2 (C-20), 117.2 (C-30); ESI-MS (m/z, %): 367 (M++Na, 100),
345 (M++H, 65); HRMS C22H16O4Na, calculated 367.0946;
found 367.0949; X-ray data are shown in Figure S3.
3-(1-(Prop-2-ynoxy)-4-oxocyclohexa-2,5-dienyl)-1H-benzo
[f]chromen-1-one (18). Yield: 45% (26.7 mg), NP-HPLC:
9.527 min (Figure S20), purity: 99.6%; transparent crystals, mp:
142–145uC, 1H NMR (CDCl3) d 9.95 (1H, d, J=7.4 Hz, H-5),
8.04 (1H, d, J=9.2 Hz, H-9), 7.87 (1H, d, br, J=8.0 Hz, H-8),
7.74 (1H, td, J=8.4, 1.6 Hz, H-7), 7.60 (1H, td, J=8.2, 1.0 Hz,
H-6), 7.37 (1H, d, J=9.2 Hz, H-10), 6.97 (2H, d, J=10.4 Hz,
H-29 and H-69), 6.91 (1H, s, H-3), 6.59 (2H, d, J=10.4 Hz, H-39
and H-59), 4.26 (2H, d, J=2.6 Hz, H-10), 2.55 (1H, t, J=2.4 Hz,
H-30) (Figures S58, S59 and S60); 13C NMR (CDCl3) d 183.9 (C-
49), 179.3 (C-4), 159.9 (C-2), 156.9 (C-10a), 144.2 (C-29 and C-
69), 132.6 (C-39 and C-59), 135.4, 130.2, 129.8, 129.1, 127.8,
126.6, 126.5 (C-4b, C-5, C-6, C-7, C-8, C-8a, C-9), 116.8 (C-10),
116.8 (C-4a), 112.2 (C-3), 74.6 (C-19), 53.2 (C-10), 75.7 (C-
30),79.0 (C-20); ESI-MS (m/z, %): 365 (M++Na, 100), 343
(M++H, 52); HRMS C22H14O4Na, calculated 365.0790; found
365.0788.
Supporting Information
Figure S1 X-ray diffraction data for compound 8. CCDC
762721; formula: C18H14O6; unit cell parameters: a 6.9461(20) b
30.2804(66) c 7.6340(13) beta 93.752(19) space group P21/c.
(TIF)
Figure S2 X-ray diffraction data for compound 14.
CCDC 762722; formula: C22H18O4; unit cell parameters: a
7.8452(8) b 25.285(5) c 18.144(2) beta 96.096(9) space group P21/c.
(TIF)
Figure S3 X-ray diffraction data for compound 17.
CCDC 762723; formula: C22H16O4; unit cell parameters: a
7.9122(8) b 24.817(5) c 17.8259(16) beta 96.380(8) space group P21/c.
(TIF)
Figure S4 RP-HPLC chromatogram of compound 1.
Solvent: 35% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 35%; flow rate: 1 mL/min,
l=245 nm
(TIF)
Figure S5 RP-HPLC chromatogram of compound 10.
Solvent: 35% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 35%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S6 RP-HPLC chromatogram of compound 3.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S7 RP-HPLC chromatogram of compound 4.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S8 RP-HPLC chromatogram of compound 5.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S9 RP-HPLC chromatogram of compound 6.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S10 RP-HPLC chromatogram of compound 7.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S11 RP-HPLC chromatogram of compound 8.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Figure S12 RP-HPLC chromatogram of compound 9.
Solvent: 55% v/v aqueous MeOH increasing to 80% in 10 min
and subsequently changing back to 55%; flow rate:1 mL/min,
l=245 nm
(TIF)
Economic Synthesis of Protoapigenone & Derivatives
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23922
Figure S13 NP-HPLC chromatogram of compound 11.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S14 NP-HPLC chromatogram of compound 12.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S15 NP-HPLC chromatogram of compound 13.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S16 NP-HPLC chromatogram of compound 14.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S17 NP-HPLC chromatogram of compound 15.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S18 NP-HPLC chromatogram of compound 16.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S19 NP-HPLC chromatogram of compound 17.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S20 NP-HPLC chromatogram of compound 18.
Solvent: 5% v/v isopropanol in dichloromethane increasing to
17% in 12 min; flow rate:1 mL/min, l=245 nm
(TIF)
Figure S21 400 MHz 1H NMR spectrum of compound 10.
(TIF)
Figure S22 Zoom of 400 MHz 1H NMR spectrum of
compound 10.
(TIF)
Figure S23 200 MHz 1H NMR spectrum of compound 3
before crystallization.
(TIF)
Figure S24 Zoom of 200 MHz 1H NMR spectrum of
compound 3 before crystallization.
(TIF)
Figure S25 200 MHz 1H NMR spectrum of compound 4
before crystallization.
(TIF)
Figure S26 Zoom of 200 MHz 1H NMR spectrum of
compound 4 before crystallization.
(TIF)
Figure S27 Zoom of 200 MHz 1H NMR spectrum of
compound 4 before crystallization.
(TIF)
Figure S28 200 MHz 1H NMR spectrum of compound 5
before crystallization.
(TIF)
Figure S29 Zoom of 200 MHz 1H NMR spectrum of
compound 5 before crystallization.
(TIF)
Figure S30 Zoom of 200 MHz 1H NMR spectrum of
compound 5 before crystallization.
(TIF)
Figure S31 200 MHz 1H NMR spectrum of compound 6
before crystallization.
(TIF)
Figure S32 Zoom of 200 MHz 1H NMR spectrum of
compound 6 before crystallization.
(TIF)
Figure S33 Zoom of 200 MHz 1H NMR spectrum of
compound 6 before crystallization.
(TIF)
Figure S34 Zoom of 200 MHz 1H NMR spectrum of
compound 6 before crystallization.
(TIF)
Figure S35 200 MHz 1H NMR spectrum of compound 7
before crystallization.
(TIF)
Figure S36 Zoom of 200 MHz 1H NMR spectrum of
compound 7 before crystallization.
(TIF)
Figure S37 Zoom of 200 MHz 1H NMR spectrum of
compound 7 before crystallization.
(TIF)
Figure S38 200 MHz 1H NMR spectrum of compound 8
before crystallization.
(TIF)
Figure S39 Zoom of 200 MHz 1H NMR spectrum of
compound 8 before crystallization.
(TIF)
Figure S40 200 MHz 1H NMR spectrum of compound 9
before crystallization.
(TIF)
Figure S41 Zoom of 200 MHz 1H NMR spectrum of
compound 9 before crystallization.
(TIF)
Figure S42 400 MHz 1H NMR spectrum of compound 9
before crystallization.
(TIF)
Figure S43 200 MHz 1H NMR spectrum of compound 13
before crystallization.
(TIF)
Figure S44 Zoom of 200 MHz 1H NMR spectrum of
compound 13 before crystallization.
(TIF)
Figure S45 Zoom of 200 MHz 1H NMR spectrum of
compound 13 before crystallization.
(TIF)
Figure S46 200 MHz 1H NMR spectrum of compound 14
before crystallization.
(TIF)
Figure S47 Zoom of 200 MHz 1H NMR spectrum of
compound 14 before crystallization.
(TIF)
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Figure S48 Zoom of 200 MHz 1H NMR spectrum of
compound 14 before crystallization.
(TIF)
Figure S49 200 MHz 1H NMR spectrum of compound 15
before crystallization.
(TIF)
Figure S50 Zoom of 200 MHz 1H NMR spectrum of
compound 15 before crystallization.
(TIF)
Figure S51 Zoom of 200 MHz 1H NMR spectrum of
compound 15 before crystallization.
(TIF)
Figure S52 200 MHz 1H NMR spectrum of compound 16
before crystallization.
(TIF)
Figure S53 Zoom of 200 MHz 1H NMR spectrum of
compound 16 before crystallization.
(TIF)
Figure S54 Zoom of 200 MHz 1H NMR spectrum of
compound 16 before crystallization.
(TIF)
Figure S55 200 MHz 1H NMR spectrum of compound 17
before crystallization.
(TIF)
Figure S56 Zoom of 200 MHz 1H NMR spectrum of
compound 17 before crystallization.
(TIF)
Figure S57 Zoom 200 MHz 1H NMR spectrum of
compound 17 before crystallization.
(TIF)
Figure S58 200 MHz 1H NMR spectrum of compound 18
before crystallization.
(TIF)
Figure S59 Zoom of 200 MHz 1H NMR spectrum of
compound 18 before crystallization.
(TIF)
Figure S60 Zoom of 200 MHz 1H NMR spectrum of
compound 18 before crystallization.
(TIF)
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